Predictive value of low interleukin-33 in critically ill patients

Cytokine

Volumn 103, Issue , 2018, Pages 109-113

  Krychtiuk, Konstantin A ^a,b   Stojkovic, Stefan ^a,b   Lenz, Max ^a,b   Brekalo, Mira ^a   Huber, Kurt ^b,c   Wojta, Johann ^a,b   Heinz, Gottfried ^a   Demyanets, Svitlana ^a   Speidl, Walter S ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Ludwig Boltzmann Cluster for Rheumatology   (Austria)

^c WILHELMINEN HOSPITAL   (Austria)

Author keywords

30 day mortality; Critical care; Interleukin 33; SIRS; Soluble ST2

Indexed keywords

INTERLEUKIN 33; SOMATOSTATIN RECEPTOR 2; IL1RL1 PROTEIN, HUMAN; IL33 PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN;

ADULT; AGED; APACHE; ARTICLE; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MORTALITY RISK; OBSERVATIONAL STUDY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; BLOOD; CLINICAL TRIAL; CRITICAL ILLNESS; INTENSIVE CARE UNIT;

AGED; CRITICAL ILLNESS; FEMALE; HUMANS; INTENSIVE CARE UNITS; INTERLEUKIN-1 RECEPTOR-LIKE 1 PROTEIN; INTERLEUKIN-33; MALE; MORTALITY; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES;

EID: 85041761910     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2017.09.017     Document Type: Article

References (38)

1. Brun-Buisson, C., The epidemiology of the systemic inflammatory response. Intens. Care Med. 26:Suppl 1 (2000), S64–74.
2. Bone, R.C., Sprung, C.L., Sibbald, W.J., Definitions for sepsis and organ failure. Crit. Care Med. 20 (1992), 724–726.
3. Singer, M., Deutschman, C.S., Seymour, C.W., Shankar-Hari, M., Annane, D., Bauer, M., Bellomo, R., Bernard, G.R., Chiche, J.D., Coopersmith, C.M., Hotchkiss, R.S., Levy, M.M., Marshall, J.C., Martin, G.S., Opal, S.M., Rubenfeld, G.D., van der Poll, T., Vincent, J.L., Angus, D.C., The third international consensus definitions for sepsis and septic shock (sepsis-3). Jama 315 (2016), 801–810.
4. Krychtiuk, K.A., Ruhittel, S., Hohensinner, P.J., Koller, L., Kaun, C., Lenz, M., Bauer, B., Wutzlhofer, L., Draxler, D.F., Maurer, G., Huber, K., Wojta, J., Heinz, G., Niessner, A., Speidl, W.S., Mitochondrial DNA and toll-like receptor-9 are associated with mortality in critically ill patients. Crit. Care Med. 43 (2015), 2633–2641.
5. Schmitz, J., Owyang, A., Oldham, E., Song, Y., Murphy, E., McClanahan, T.K., Zurawski, G., Moshrefi, M., Qin, J., Li, X., Gorman, D.M., Bazan, J.F., Kastelein, R.A., Il-33, an interleukin-1-like cytokine that signals via the il-1 receptor-related protein st2 and induces t helper type 2-associated cytokines. Immunity 23 (2005), 479–490.
6. Martin, N.T., Martin, M.U., Interleukin 33 is a guardian of barriers and a local alarmin. Nat. Immunol. 17 (2016), 122–131.
7. Molofsky, A.B., Savage, A.K., Locksley, R.M., Interleukin-33 in tissue homeostasis, injury, and inflammation. Immunity 42 (2015), 1005–1019.
8. Oboki, K., Ohno, T., Kajiwara, N., Saito, H., Nakae, S., Il-33 and il-33 receptors in host defense and diseases. Allergol. Int.: official journal of the Japanese Society of Allergology. 59 (2010), 143–160.
9. Liew, F.Y., Pitman, N.I., McInnes, I.B., Disease-associated functions of il-33: The new kid in the il-1 family. Nat. Rev. Immunol. 10 (2010), 103–110.
10. Stojkovic, S., Kaun, C., Basilio, J., Rauscher, S., Hell, L., Krychtiuk, K.A., Bonstingl, C., de Martin, R., Groger, M., Ay, C., Holnthoner, W., Eppel, W., Neumayer, C., Huk, I., Huber, K., Demyanets, S., Wojta, J., Tissue factor is induced by interleukin-33 in human endothelial cells: a new link between coagulation and inflammation. Sci. Rep., 6, 2016, 25171.
11. Stojkovic, S., Kaun, C., Heinz, M., Krychtiuk, K.A., Rauscher, S., Lemberger, C.E., de Martin, R., Groger, M., Petzelbauer, P., Huk, I., Huber, K., Wojta, J., Demyanets, S., Interleukin-33 induces urokinase in human endothelial cells–possible impact on angiogenesis. J. Thrombos. and Haemostasis: JTH 12 (2014), 948–957.
12. Demyanets, S., Speidl, W.S., Tentzeris, I., Jarai, R., Katsaros, K.M., Farhan, S., Krychtiuk, K.A., Wonnerth, A., Weiss, T.W., Huber, K., Wojta, J., Soluble st2 and interleukin-33 levels in coronary artery disease: relation to disease activity and adverse outcome. PloS One, 9, 2014, e95055.
13. Demyanets, S., Tentzeris, I., Jarai, R., Katsaros, K.M., Farhan, S., Wonnerth, A., Weiss, T.W., Wojta, J., Speidl, W.S., Huber, K., An increase of interleukin-33 serum levels after coronary stent implantation is associated with coronary in-stent restenosis. Cytokine 67 (2014), 65–70.
14. Demyanets, S., Konya, V., Kastl, S.P., Kaun, C., Rauscher, S., Niessner, A., Pentz, R., Pfaffenberger, S., Rychli, K., Lemberger, C.E., de Martin, R., Heinemann, A., Huk, I., Groger, M., Maurer, G., Huber, K., Wojta, J., Interleukin-33 induces expression of adhesion molecules and inflammatory activation in human endothelial cells and in human atherosclerotic plaques. Arterioscleros. Thrombos. Vascul. Biol. 31 (2011), 2080–2089.
15. Zeyda, M., Wernly, B., Demyanets, S., Kaun, C., Hammerle, M., Hantusch, B., Schranz, M., Neuhofer, A., Itariu, B.K., Keck, M., Prager, G., Wojta, J., Stulnig, T.M., Severe obesity increases adipose tissue expression of interleukin-33 and its receptor st2, both predominantly detectable in endothelial cells of human adipose tissue. Int. J. Obesity 37 (2013), 658–665.
16. Stojkovic, S., Thulin, A., Hell, L., Thaler, B., Rauscher, S., Baumgartner, J., Groger, M., Ay, C., Demyanets, S., Neumayer, C., Huk, I., Spittler, A., Huber, K., Wojta, J., Siegbahn, A., Aberg, M., Il-33 stimulates the release of procoagulant microvesicles from human monocytes and differentially increases tissue factor in human monocyte subsets. Thrombos. Haemostas. 117 (2017), 1379–1390.
17. Alves-Filho, J.C., Sonego, F., Souto, F.O., Freitas, A., Verri, W.A. Jr., Auxiliadora-Martins, M., Basile-Filho, A., McKenzie, A.N., Xu, D., Cunha, F.Q., Liew, F.Y., Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection. Nat. Med. 16 (2010), 708–712.
18. Sanada, S., Hakuno, D., Higgins, L.J., Schreiter, E.R., McKenzie, A.N., Lee, R.T., Il-33 and st2 comprise a critical biomechanically induced and cardioprotective signaling system. J. Clinic. Invest. 117 (2007), 1538–1549.
19. Lax, A., Sanchez-Mas, J., Asensio-Lopez, M.C., Fernandez-Del Palacio, M.J., Caballero, L., Garrido, I.P., Pastor-Perez, F.J., Januzzi, J.L., Pascual-Figal, D.A., Mineralocorticoid receptor antagonists modulate galectin-3 and interleukin-33/st2 signaling in left ventricular systolic dysfunction after acute myocardial infarction. JACC Heart Failure 3 (2015), 50–58.
20. Yancy, C.W., Jessup, M., Bozkurt, B., Butler, J., Casey, D.E. Jr., Drazner, M.H., Fonarow, G.C., Geraci, S.A., Horwich, T., Januzzi, J.L., Johnson, M.R., Kasper, E.K., Levy, W.C., Masoudi, F.A., McBride, P.E., McMurray, J.J., Mitchell, J.E., Peterson, P.N., Riegel, B., Sam, F., Stevenson, L.W., Tang, W.H., Tsai, E.J., Wilkoff, B.L., American Heart Association Task Force on Practice G. 2013 accf/aha guideline for the management of heart failure: a report of the american college of cardiology foundation/american heart association task force on practice guideline. J. Am. Coll. Cardiol. 2013:62 (2013), e147–239.
21. Hoogerwerf, J.J., Tanck, M.W., van Zoelen, M.A., Wittebole, X., Laterre, P.F., van der Poll, T., Soluble st2 plasma concentrations predict mortality in severe sepsis. Intens. Care Med. 36 (2010), 630–637.
22. Dieplinger, B., Egger, M., Koehler, W., Firlinger, F., Poelz, W., Lenz, K., Haltmayer, M., Mueller, T., Prognostic value of soluble st2 in an unselected cohort of patients admitted to an intensive care unit - the linz intensive care unit (licu) study. Clinica chimica acta; Int. J. Clin. Chem. 413 (2012), 587–593.
23. Krychtiuk, K.A., Honeder, M.C., Lenz, M., Maurer, G., Wojta, J., Heinz, G., Huber, K., Speidl, W.S., Copeptin predicts mortality in critically ill patients. PloS One, 12, 2017, e0170436.
24. Krychtiuk, K.A., Lenz, M., Koller, L., Honeder, M.C., Wutzlhofer, L., Zhang, C., Chi, L., Maurer, G., Niessner, A., Huber, K., Wojta, J., Heinz, G., Speidl, W.S., Monocyte subset distribution is associated with mortality in critically ill patients. Thrombos. Haemostas. 116 (2016), 949–957.
25. Knaus, W.A., Draper, E.A., Wagner, D.P., Zimmerman, J.E., Apache ii: a severity of disease classification system. Crit. Care Med. 13 (1985), 818–829.
26. Dieplinger, B., Egger, M., Leitner, I., Firlinger, F., Poelz, W., Lenz, K., Haltmayer, M., Mueller, T., Interleukin 6, galectin 3, growth differentiation factor 15, and soluble st2 for mortality prediction in critically ill patients. Journal of critical care. 34 (2016), 38–45.
27. Pastorelli, L., Garg, R.R., Hoang, S.B., Spina, L., Mattioli, B., Scarpa, M., Fiocchi, C., Vecchi, M., Pizarro, T.T., Epithelial-derived il-33 and its receptor st2 are dysregulated in ulcerative colitis and in experimental th1/th2 driven enteritis. Proc. Nat. Acad. Sci. USA 107 (2010), 8017–8022.
28. Matsuyama, Y., Okazaki, H., Tamemoto, H., Kimura, H., Kamata, Y., Nagatani, K., Nagashima, T., Hayakawa, M., Iwamoto, M., Yoshio, T., Tominaga, S., Minota, S., Increased levels of interleukin 33 in sera and synovial fluid from patients with active rheumatoid arthritis. J. Rheumatol. 37 (2010), 18–25.
29. Yanaba, K., Yoshizaki, A., Asano, Y., Kadono, T., Sato, S., Serum il-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. Clin. Rheumatol. 30 (2011), 825–830.
30. Xia, J., Zhao, J., Shang, J., Li, M., Zeng, Z., Zhao, J., Wang, J., Xu, Y., Xie, J., Increased il-33 expression in chronic obstructive pulmonary disease. Am. J. Physiol. Lung Cell. Mol. Physiol. 308 (2015), L619–627.
31. Brunner, M., Krenn, C., Roth, G., Moser, B., Dworschak, M., Jensen-Jarolim, E., Spittler, A., Sautner, T., Bonaros, N., Wolner, E., Boltz-Nitulescu, G., Ankersmit, H.J., Increased levels of soluble st2 protein and igg1 production in patients with sepsis and trauma. Intens. Care Med. 30 (2004), 1468–1473.
32. Oshikawa, K., Kuroiwa, K., Tago, K., Iwahana, H., Yanagisawa, K., Ohno, S., Tominaga, S.I., Sugiyama, Y., Elevated soluble st2 protein levels in sera of patients with asthma with an acute exacerbation. Am. J. Respirat. Crit. Care Med. 164 (2001), 277–281.
33. Benoit, J.L., Hicks, C.W., Engineer, R.S., Hart, K.W., Lindsell, C.J., Peacock, W.F., St2 in emergency department patients with noncardiac dyspnea. Acad. Emerg. Med.: official journal of the Society for Academic Emergency Medicine 20 (2013), 1207–1210.
34. Jawa, R.S., Anillo, S., Huntoon, K., Baumann, H., Kulaylat, M., Interleukin-6 in surgery, trauma, and critical care part ii: clinical implications. J. Intens. Care Med. 26 (2011), 73–87.
35. Pierrakos, C., Vincent, J.L., Sepsis biomarkers: a review. Critical Care, 14, 2010, R15.
36. Li, S., Zhu, F.X., Zhao, X.J., An, Y.Z., The immunoprotective activity of interleukin-33 in mouse model of cecal ligation and puncture-induced sepsis. Immunol. Lett. 169 (2016), 1–7.
37. Lan, F., Yuan, B., Liu, T., Luo, X., Huang, P., Liu, Y., Dai, L., Yin, H., Interleukin-33 facilitates neutrophil recruitment and bacterial clearance in s. Aureus-caused peritonitis. Molecul. Immunol. 72 (2016), 74–80.
38. Lv, R., Zhao, J., Lei, M., Xiao, D., Yu, Y., Xie, J., Il-33 attenuates sepsis by inhibiting il-17 receptor signaling through upregulation of socs3. Cellular Physiol. Biochem.: international journal of experimental cellular physiology, biochemistry, and pharmacology. 42 (2017), 1961–1972.